Products with Antileukaemic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2961 | Ingenol 3-Angelate |
| 1. Ingenol-3-angelate suppresses HIV infection of primary CD4+ T cells through down-modulation of cell surface expression of HIV co-receptors. 2. Ingenol 3-angelate activates a broad range of PKC isoforms and induces apoptosis in acute myeloid leukemia cells by activating the PKC isoform PKCdelta. 3. Ingenol-3-angelate shows anticancer activity, and P-gp-mediated absorptive transport, dermal penetration, and vascular damage contribute to the anticancer activity of ingenol-3-angelate in vivo. 4. Ingenol-3-angelate emerges as a unique local chemotherapeutic immunostimulatory debulking agent that could be used in conjunction with immunotherapies to promote regression of metastases. | |
| BCN3128 | Isochamaejasmine |
| Isochamaejasmine has inhibition of NF-kappaB activation, which could reverse the anti-apoptotic effect; it induces apoptosis in leukemia cells by inhibiting the activity of Bcl-2 family proteins, providing evidence for further studying the underlying anti-cancer mechanism of S. chamaejasme L. Isochamaejasmine shows antiplasmodial activity, with an IC(50) of 7.3+/-3.8 microM, but the selectivity was rather limited. | |
| BCN3176 | Mahanine |
| 1. Mahanine has a dose- and time-dependent anti-proliferative activity in acute lymphoid (MOLT-3) and chronic myeloid (K562) leukemic cell lines. 2. Mahanine has effects on the activation of the apoptotic pathway in human leukemia U937 cells, causes the mitochondrial membranes to lose their permeability, resulting in caspase-3 activation and apoptosis. 3. Mahanine can reverse an epigenetically silenced gene, RASSF1A in prostate cancer cells by inhibiting DNMT activity that in turn down-regulates a key cell cycle regulator, cyclin D1, is an encouraging therapeutic choice for advanced prostatic cancer. 4. Mahanine inhibited growth of PC3 and LNCaP prostate cancer cells in a dose and time-dependent manner, inhibits growth and induces apoptosis in both androgen-responsive, LNCaP and androgen-independent, PC3 cells by targeting cell survival pathway. | |
| BCN3224 | Voacangine |
| 1. Voacangine is a novel transient receptor potential vanilloid type 1 (TRPV1) antagonist. 2. Voacangine shows mod. cytotoxic activity, also some CNS, brachycardial and hypotensive action. 3. Voacangine significantly suppresses in vitro angiogenesis, such as VEGF-induced tube formation and chemoinvasion. 4. Voacangine competitively inhibits the binding of menthol to TRPM8 (IC50, 9 μM), but it shows noncompetitive inhibition against icilin (IC50, 7 μM), it may contribute to the development of a novel class of stimulus-selective TRPM8 blockers. | |
| BCN3231 | Ponicidin |
| 1. Ponicidin has immunoregulatory and anti-inflammatory functions . 2. Ponicidin has anti-viral function especially in the upper respiratory tract infection. 3. Ponicidin has anti-leukemia activity, by inducing apoptosis, downregulation of survivin as well as Bcl-2 expressions. 4. Ponicidin has anti-cancer activity against gastric carcinoma and lung cancer; can inhibit growth and induce apoptosis of gastric carcinoma cell line MKN28, via the signaling pathway regulated by Janus kinase 2 (JAK2) and signal transducers and activators of transcription 3 (STAT3). | |
